Related Experiment Video
Updated: Apr 11, 2026
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Operationalizing a Decision-Making for Adverse Event Reporting Toolkit (DART) for Aging and Serious Illness Research
Sara Lubetsky1, Christopher Woodrell1,2, Gabrielle Schiller1
1Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Introduction:
Monitoring adverse events (AEs) assures patient safety in clinical trials. Studies involving seriously ill and older adults can have a high volume of AEs related to underlying courses of illness rather than study procedures. Trials not regulated by the Food and Drug Administration (FDA) can incur excessive reporting burden beyond that required for compliance or patient safety assurance. In 2021, a working group proposed an alternative approach to AE evaluation, emphasizing routine, aggregate reporting, and reserving expedited reporting of individual AEs for serious events at least possibly related to study procedures and not aligned with goals of care. Another outcome was a call to operationalize the approach for eventual implementation.
Methods:
A panel comprising 31 leaders from government agencies, professional organizations, aging and serious illness research communities, research administration, and medical ethics met five times in 2024-2025. The panel advised on deliverables, assessed concept acceptability, and reviewed tools; a multidisciplinary project team generated content and incorporated feedback. Research compliance experts reviewed the final decision algorithm.
Results:
The resulting Decision-Making for Adverse Event Reporting Toolkit Tailored to Social, Behavioral and Health Services Studies involving Seriously Ill and Older Adult Populations (DART) is a novel research tool to support researchers in AE evaluation. The decision algorithm assesses: (1) relatedness, (2) goals of care alignment, (3) seriousness, and (4) greater risk of harm. The toolkit includes a case series, frequently asked questions, and reporting form. Feedback emphasized DART applies to any study population and intervention type not regulated by the FDA.
Conclusions:
DART provides a novel solution to AE reporting challenges faced by aging and serious illness researchers. While its design centers on seriously ill older adults, DART can likely be applied to research in any population and intervention type not regulated by the FDA. Future pilot testing will inform implementation.
Insights
The new Decision-Making for Adverse Event Reporting Toolkit (DART) simplifies adverse event reporting for clinical trials not regulated by the FDA. This tool helps researchers focus on serious events possibly related to study procedures, reducing reporting burdens.
Area of Science:
- Clinical Trials
- Patient Safety
- Regulatory Science
Background:
- Adverse events (AEs) monitoring is crucial for patient safety in clinical trials.
- Studies in seriously ill and older adults often have high AE volumes due to underlying conditions.
- Non-Food and Drug Administration (FDA)-regulated trials face reporting burdens beyond safety needs.
Purpose of the Study:
- To operationalize a proposed alternative approach for AE evaluation in clinical research.
- To develop a practical tool for researchers to streamline AE reporting.
- To reduce unnecessary reporting burdens in non-FDA-regulated studies.
Main Methods:
- A 31-member expert panel convened multiple times between 2024-2025.
- The panel provided guidance on deliverables, concept acceptability, and tool review.
- A multidisciplinary team developed content, incorporated feedback, and compliance experts validated the algorithm.
Main Results:
- The Decision-Making for Adverse Event Reporting Toolkit Tailored to Social, Behavioral and Health Services Studies involving Seriously Ill and Older Adult Populations (DART) was developed.
- DART features a decision algorithm assessing relatedness, goals of care alignment, seriousness, and harm risk.
- The toolkit includes a case series, FAQs, and a reporting form; feedback indicated broad applicability beyond the target population.
Conclusions:
- DART offers an innovative solution for AE reporting challenges in aging and serious illness research.
- The toolkit is adaptable for research in any population and intervention type not regulated by the FDA.
- Future pilot testing is planned to guide DART's implementation.
More Related Videos
06:05The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
03:47Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Related Concept Videos
01:30Ethical Dilemmas II
01:15Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
01:21Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:14SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
01:21Methods of Documentation III: PIE